Article
Oncology
Rayne Peerenboom, Ankit Dhiman, Hunter D. D. Witmer, Liam F. Spurr, Blase Polite, Oliver S. Eng, Ardaman Shergill, Kiran K. Turaga
Summary: This study analyzed the impact of tumor biology on survival outcomes in colorectal cancer patients with peritoneal metastasis undergoing optimal cytoreductive surgery (CRS). The study found that alterations in the PI3K pathway were associated with earlier recurrence following optimal CRS, suggesting a distinct molecular subtype.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Christopher A. Klebanoff, Smita S. Chandran
Summary: PIK3CA gain-of-function mutations are common in human solid cancers. Using SIFT-seq, a panel of TCRs that bind a mutant PI3K alpha shared neoantigen was identified, including a potential clinical candidate that interacts with cancer cells through a distinctive CDR3 beta loop.
Article
Oncology
Theodora Pappa, Sara Ahmadi, Ellen Marqusee, Hannah L. Johnson, Matthew A. Nehs, Nancy L. Cho, Justine A. Barletta, Jochen H. Lorch, Gerard M. Doherty, Neal I. Lindeman, Erik K. Alexander, Inigo Landa
Summary: Routine genomic sequencing was used to identify additional oncogenic alterations in BRAF(v600E)-mutant papillary thyroid carcinoma (PTC) patients, which were associated with increased risk of recurrence, larger tumor size, and more advanced stage at presentation. Independent oncogenic mutations in the PI3K/AKT/mTOR pathway were also found to be significantly associated with disease-specific mortality (DSM), highlighting the importance of genomic profiling for prognosis and clinical strategy in PTC.
CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Huimin Zhu, Wanbo Zeng, Tangna Zhao, Weiguo Shi, Xiao Dong, Aiping Zhang, Xiang Li, Liang Xu
Summary: This study synthesized six derivatives of AICAR and evaluated their anti-fatigue effects. The optimal compound ZHM-01 exhibited significant anti-fatigue effects in animal models, while also demonstrating good biological safety.
ARABIAN JOURNAL OF CHEMISTRY
(2022)
Article
Agriculture, Dairy & Animal Science
Soo-Hyeon Kim, Byung-Joon Seung, Seung-Hee Cho, Ha-Young Lim, Min-Kyung Bae, Jung-Hyang Sur
Summary: The frequency of PIK3CA H1047R mutation in canine mammary tumors is 14.3%, leading to dysregulation of downstream molecules Akt2, p-Akt, and PTEN, with the exception of a higher level of PTEN in mutated tumors. No significant correlation was found between PIK3CA H1047R mutation and expression of downstream molecules, suggesting the dysregulation of components in the PI3K/Akt/PTEN pathway is a feature in canine mammary tumors distinct from the mutation.
Article
Virology
Ye Wei, Shitong Lin, Wenhua Zhi, Tian Chu, Binghan Liu, Ting Peng, Miaochun Xu, Wencheng Ding, Canhui Cao, Peng Wu
Summary: Cervical carcinoma is a serious gynecological cancer with potential targets in the PI3K/AKT pathways. The study found that PIK3CA mutation is common in cervical carcinoma, and Alpelisib can inhibit the growth of PIK3CA-mutant cancer cells and enhance cisplatin efficacy. This study provides insights into the potential use of Alpelisib in precision medicine for cervical carcinoma.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Rosalin Mishra, Hima Patel, Samar Alanazi, Mary Kate Kilroy, Joan T. Garrett
Summary: The PI3K pathway is crucial in cancer development and is a promising therapeutic target. Clinical trials are ongoing to evaluate the efficacy and potential risks associated with PI3K inhibitors in overcoming resistance to current therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Ram Hari Pokhrel, Suman Acharya, Jae-Hee Ahn, Ye Gu, Mahesh Pandit, Jong-Oh Kim, Yun-Yong Park, Ben Kang, Hyun-Jeong Ko, Jae-Hoon Chang
Summary: In this study, it was found that AMP-activated protein kinase (AMPK) plays a regulatory role in the expression of PD-1 through the HMGCR/p38 MAPK/GSK3 beta signaling pathway in regulatory T cells (Tregs). This suggests that AMPK activators may have synergistic antitumor effects in murine tumor models when combined with other treatments.
Article
Biology
Floyd Hassenrueck, Maria Farina-Morillas, Lars Neumann, Francesco Landini, Stuart James Blakemore, Mina Rabipour, Juan Raul Alvarez-Idaboy, Christian P. Pallasch, Michael Hallek, Rocio Rebollido-Rios, Guenter Krause
Summary: Cell-based and molecular exploration provides comparative characterization of currently developed PI3K inhibitors and structural insights for future inhibitor design. The study focuses on targeting the PI3K isoform p110 delta against B cell malignancies and evaluates the potency, isoform-selectivity, and molecular interactions of various PI3Ki chemotypes. The I777M substitution affects the efficacy and selectivity of p110 delta-selective inhibitors, but not multi-targeted inhibitors, due to its effect on the conformational flexibility of p110 delta's specificity or affinity pockets. This research provides valuable information for optimizing PI3Ki design.
COMMUNICATIONS BIOLOGY
(2023)
Article
Oncology
Ariadna Brito, Candice Merle, Pauline Lagarde, Benjamin Faustin, Anne Devin, Lydia Lartigue, Frederic Chibon
Summary: The study found that cell-to-cell fusion hybrids have a strong metabolic activity, relying on enhanced glycolysis for proliferation, while the drug AICAR can effectively inhibit their growth and invasive capacity by modulating the metabolic equilibrium, suggesting a potential novel therapeutic strategy for cancer treatment.
Article
Immunology
Shih-Hsiu Chou, Tsai-Wen Wan, Chung-Wai Shiau, Ling -Han Chen, Hsueh-Chun Lin, Hao-Chieh Chiu
Summary: In this study, it was found that the tyrosine kinase inhibitor nilotinib has antibacterial activity against intracellular Salmonella enterica. The aim was to exploit the antibacterial activity of nilotinib and understand its mechanism of action.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Editorial Material
Oncology
Aakash Desai, Vivek Subbiah
Summary: Immunotherapy has shown benefits in some cancer cases, but most patients still face cancer progression despite treatment. Precision-driven patient selection is proposed to identify successful combinations of immunotherapy for improved outcomes.
Article
Medicine, Research & Experimental
Sushmita Mustafi, Vladimir Camarena, Rehana Qureshi, David W. Sant, Zachary Wilkes, Daniel Bilbao, Joyce Slingerland, Susan B. Kesmodel, Gaofeng Wang
Summary: The study demonstrated that vitamin C can synergistically enhance the anti-cancer effects of buparlisib in treating PIK3CA-mutated triple negative breast cancer cells, leading to reduced dosage requirements and potential mitigation of dose-dependent side effects. Vitamin C modulates PI3K pathway gene expression, inhibits AKT phosphorylation, and works in coordination with buparlisib to inhibit cancer cell growth.
Article
Oncology
Tony K. H. Chung, Graeme Doran, Tak-Hong Cheung, So-Fan Yim, Mei-Yung Yu, Michael J. Worley, Kevin M. Elias, Aaron R. Thorner, Chandra Sekhar Pedamallu, Akinyemi I. Ojesina, Kei-Man Lau, Matthew D. Ducar, Raymond R. Y. Wong, Vivian W. Wang, Anwesha Nag, Bruce M. Wollison, Audrey Dalgarno, Jacqueline H. S. Lee, Suet-Ying Yeung, Lo Wong, Neil S. Horowitz, Michelle R. Davis, Shuk-On A. Leung, Yi Mu, Samuel C. Mok, Paul K. S. Chan, Michael S. Lawrence, Christopher P. Crum, Rossa W. K. Chiu, Ross S. Berkowitz, Yick-Fu Wong
Summary: In this study, PIK3CA mutations were found to be significantly associated with survival outcomes in cervical adenocarcinoma patients, highlighting the potential for personalized treatment and liquid biopsies in managing this specific type of women's cancer.
Article
Pharmacology & Pharmacy
Lijun Kong, Hewei Zhang, Chaosheng Lu, Keqing Shi, Hongjian Huang, Yushu Zheng, Yongqiang Wang, Dan Wang, Hongwei Wang, Wei Huang
Summary: AICAR activation of AMPK significantly ameliorates PALI, with hepatic AMPK activation playing a crucial protective role in PALI. AICAR-induced AMPK activation protects rats from PALI by regulating hepatic antioxidant capacity through Nrf2 and inhibiting NLRP3 inflammasome activation.
FRONTIERS IN PHARMACOLOGY
(2021)